New research indicates that CBD and metformin could play a crucial role in managing behavioral difficulties in genetic conditions such as Fragile X and Phelan-McDermid syndromes. By correcting brain biochemistry and modifying behavior in mouse models, these substances offer hope for developing effective treatments for these disorders in humans. New research highlights how cannabidiol and metformin can alleviate behavioral difficulties in mouse models of Fragile X and Phelan-McDermid syndromes.
These treatments have been shown to improve behavioral symptoms, with further research underway to explore their potential applications in humans. Studies of mouse models of Fragile X syndrome and Phelan-McDermid syndrome show that treatment with cannabidiol (CBD) and the diabetes drug metformin can alleviate behavioral difficulties. This is according to research that will be presented on June 26 at the Federation of European Neuroscience Societies (FENS) Forum 2024.
[1] Fragile X syndrome and Phelan-McDermid syndrome are two genetic conditions that cause a variety of neurodevelopmental difficulties throughout life. Both conditions have a high incidence of autism spectrum disorder , including speech delay, social difficulties, and repetitive behavior. The research was presented by Dr.
Ilse Gantois from McGill University, Montreal, Canada. She said: “There are several drugs used to treat depression, anxiety, epilepsy and aggression in people with Fragile X. Most of these drugs have man.